Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Locations: - Veterans Administration Medical Center - Birmingham — Birmingham, Alabama
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
- Thomas Hospital — Fairhope, Alabama
+ 1226 more sites in the U.S.
Phase 3 Recruiting NIH
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Locations: - Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
+ 601 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Locations: - Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
+ 253 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Locations: - Local Institution - 007-556-A — Goodyear, Arizona
- USOR - Arizona Oncology - Prescott Valley — Prescott Valley, Arizona
- Local Institution - 007-568-A — Safford, Arizona
+ 217 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Locations: - Alabama Oncology — Alabaster, Alabama
- Alabama Oncology — Bessemer, Alabama
- Alabama Oncology, Bruno Cancer Center — Birmingham, Alabama
+ 130 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC)…
Sponsor: AstraZeneca
NCT ID: NCT06692738
Locations: - Research Site — Tucson, Arizona
- Research Site — Springdale, Arkansas
- Research Site — Anaheim, California
+ 70 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Locations: - Alaska Oncology and Hematology ( Site 0039) — Anchorage, Alaska
- The University of Arizona Cancer Center - North Campus ( Site 0071) — Tucson, Arizona
- YUMA REGIONAL MEDICAL CENTER CANCER CENTER ( Site 0020) — Yuma, Arizona
+ 65 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06357533
Locations: - Research Site — Anchorage, Alaska
- Research Site — Tucson, Arizona
- Research Site — Little Rock, Arkansas
+ 60 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Locations: - Banner MD Anderson Cancer Center ( Site 0181) — Gilbert, Arizona
- The University of Arizona Cancer Center - North Campus ( Site 0163) — Tucson, Arizona
- Providence St. Jude Medical Center ( Site 0106) — Fullerton, California
+ 45 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-muta…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06793215
Locations: - Alaska Oncology and Hematology — Anchorage, Alaska
- City of Hope - Phoenix — Goodyear, Arizona
- Marin Cancer Care Inc — Greenbrae, California
+ 41 more sites in the U.S.
Phase 3 Recruiting Industry
A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361497
Locations: - Southern Cancer Center Pc — Daphne, Alabama
- Local Institution - 0780 — Chandler, Arizona
- Local Institution - 0585 — Golden, Colorado
+ 35 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Locations: - Alaska Oncology and Hematology, LLC — Anchorage, Alaska
- John Muir Clinical Research Center — Concord, California
- University Of California - San Diego Moores Cancer Center — La Jolla, California
+ 33 more sites in the U.S.